The Immunotherapy of Canine Osteosarcoma: a Historical and Systematic Review

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2015 May 2

PMID 25929293

Citations 36

Authors

K L Wycislo

T M Fan

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in humans. Despite dose intensification with conventional cytotoxic therapies, survival times for dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, with the principal cause of mortality being the development of pulmonary metastases. Given the therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is clinically justified. Evidence suggests that osteosarcoma is an immunogenic tumor, and development of immunotherapies for the treatment of microscopic lung metastases might improve long-term outcomes. In this review, the history and foundational knowledge of immune interactions to canine osteosarcoma are highlighted. In parallel, immunotherapeutic strategies that have been explored for the treatment of canine osteosarcoma are summarized. With a greater understanding and awareness for how the immune system might be redirected toward combating osteosarcoma metastases, the rational development of diverse immune strategies for managing osteosarcoma holds substantial promise for transforming the therapeutic landscape and improving disease management in both dogs and human beings.

Citing Articles

Investigating cell death responses associated with histotripsy ablation of canine osteosarcoma.

Hay A, Vickers E, Patwardhan M, Gannon J, Ruger L, Allen I Int J Hyperthermia. 2023; 40(1):2279027.

PMID: 38151477 PMC: 10764077. DOI: 10.1080/02656736.2023.2279027.

Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.

Maekawa N, Konnai S, Hosoya K, Kim S, Kinoshita R, Deguchi T PLoS One. 2023; 18(10):e0291727.

PMID: 37792729 PMC: 10550157. DOI: 10.1371/journal.pone.0291727.

Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans.

Mannheimer J, Tawa G, Gerhold D, Braisted J, Sayers C, McEachron T Commun Biol. 2023; 6(1):856.

PMID: 37591946 PMC: 10435536. DOI: 10.1038/s42003-023-05208-z.

Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.

Hambly J, Ruby C, Mourich D, Bracha S, Dolan B Vet Sci. 2023; 10(5).

PMID: 37235419 PMC: 10224056. DOI: 10.3390/vetsci10050336.

Nanocarriers in Veterinary Medicine: A Challenge for Improving Osteosarcoma Conventional Treatments.

Sapino S, Chindamo G, Chirio D, Morel S, Peira E, Vercelli C Nanomaterials (Basel). 2022; 12(24).

PMID: 36558354 PMC: 9785518. DOI: 10.3390/nano12244501.

References

Reif J, BRODEY R . Pre- and postoperative studies of in vitro cell-mediated reactivity in canine osteosarcoma. Am J Vet Res. 1978; 39(1):87-93. View

Sherger M, Kisseberth W, London C, Olivo-Marston S, Papenfuss T . Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. BMC Vet Res. 2012; 8:209. PMC: 3557223. DOI: 10.1186/1746-6148-8-209. View

Asano T, McWatters A, An T, Matsushima K, Kleinerman E . Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994; 268(2):1032-9. View

Gorman N . Alveolar macrophage cytotoxicity in dogs following intravenous BCG. Eur J Cancer (1965). 1979; 15(8):1051-9. DOI: 10.1016/0014-2964(79)90293-7. View

Rissetto K, Rindt H, Selting K, Villamil J, Henry C, Reinero C . Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma. Vet Immunol Immunopathol. 2010; 135(1-2):137-145. DOI: 10.1016/j.vetimm.2010.02.002. View

Mata M, Vera J, Gerken C, Rooney C, Miller T, Pfent C . Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014; 37(8):407-15. PMC: 4163948. DOI: 10.1097/CJI.0000000000000052. View

Koshkina N, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman E . Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007; 5(10):991-9. DOI: 10.1158/1541-7786.MCR-07-0007. View

Meyers P, Schwartz C, Krailo M, Kleinerman E, Betcher D, Bernstein M . Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23(9):2004-11. DOI: 10.1200/JCO.2005.06.031. View

Wasserman J, Diese L, VanGundy Z, London C, Carson W, Papenfuss T . Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells. Vet Immunol Immunopathol. 2012; 145(1-2):420-30. PMC: 4278197. DOI: 10.1016/j.vetimm.2011.12.018. View

10.

Rowell J, McCarthy D, Alvarez C . Dog models of naturally occurring cancer. Trends Mol Med. 2011; 17(7):380-8. PMC: 3130881. DOI: 10.1016/j.molmed.2011.02.004. View

11.

Gordon N, Koshkina N, Jia S, Khanna C, Mendoza A, Worth L . Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007; 13(15 Pt 1):4503-10. PMC: 4503209. DOI: 10.1158/1078-0432.CCR-07-0313. View

12.

BRODEY R, RISER W . Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop Relat Res. 1969; 62:54-64. View

13.

Gentschev I, Patil S, Adelfinger M, Weibel S, Geissinger U, Frentzen A . Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered. 2012; 4(2):84-9. PMC: 3609626. DOI: 10.4161/bioe.22462. View

14.

Coley W . The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 2009; 3(Surg Sect):1-48. PMC: 1961042. View

15.

Spodnick G, Berg J, Rand W, Schelling S, Couto G, Harvey H . Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc. 1992; 200(7):995-9. View

16.

Rodriguez Jr C, Crabbs T, Wilson D, Cannan V, Skorupski K, Gordon N . Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2009; 23(4):197-206. PMC: 2888930. DOI: 10.1089/jamp.2009.0773. View

17.

Thamm D, Kurzman I, King I, Li Z, Sznol M, Dubielzig R . Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 2005; 11(13):4827-34. DOI: 10.1158/1078-0432.CCR-04-2510. View

18.

ONeill K, Guth A, Biller B, Elmslie R, Dow S . Changes in regulatory T cells in dogs with cancer and associations with tumor type. J Vet Intern Med. 2009; 23(4):875-81. DOI: 10.1111/j.1939-1676.2009.0333.x. View

19.

Shi F, MacEwen E, Kurzman I . In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res. 1993; 53(17):3986-91. View

20.

Fidler I, BRODEY R . In vitro immune stimulation-inhibition to spontaneous canine tumors of various histologic types. J Immunol. 1974; 112(3):1051-60. View